ICCM IceCure Medical Ltd
USHealthcareAs of 2026-07-10 16:00
Why ICCM matters now
IceCure Medical Ltd (ICCM) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.65 with -6.17% on the session and $8.2M in market capitalization; recent performance reads 1-month -21.05% and YTD -70.49%.
The latest financial table shown here is Q1 2026, with revenue of $911.0K, net income of $-4.3M, and EPS of $-1.74. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -126.1%.
The latest indexable market news headline is "IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $1.00; recent insider activity includes Peleg Meir filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.56
P/S
3.41
EV/EBITDA
-0.27
DCF Value
$-11.86
FCF Yield
-126.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
36.5%
Operating Margin
-835.0%
Net Margin
-441.6%
ROE
-211.7%
ROA
-118.3%
ROIC
-344.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $911.0K | $-4.3M | $-1.74 |
| Q4 2025 | $1.3M | $-4.2M | $-1.75 |
| FY 2025 | $3.4M | $-15.1M | $-7.20 |
| Q3 2025 | $850.0K | $-3.9M | $-1.81 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$1.00
Target (Median)
$1.00
Target Range
$1.00 - $1.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
IL
Exchange
—
Beta
1.49
Headquartered in Caesarea, Israel, and founded in 2006, IceCure Medical Ltd is a medical device enterprise dedicated to inventing, refining, and marketing innovative solutions for treating human tumors through cryoablation, a freezing process. Their primary offering, the ProSense system, provides a specialized cryoablation therapy specifically for breast tumors.